File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: MicroRNA-16 and microRNA-193b as serological predictors for chemoradiation response in esophageal squamous cell carcinoma patients

TitleMicroRNA-16 and microRNA-193b as serological predictors for chemoradiation response in esophageal squamous cell carcinoma patients
Authors
KeywordsMedical sciences
Communicable diseases
Issue Date2015
PublisherAmerican Association for Cancer Research. The Journal's web site is located at http://www.aacrmeetingabstracts.org/
Citation
The 106th Annual Meeting of the American Association for Cancer Research (AACR 2015), Philadelphia, PA., 18-22 April 2015. In AACR Meeting Abstracts, 2015, v. 75 n. 15 suppl., abstract no. 3989 How to Cite?
AbstractEsophageal cancer is one of the most deadly malignancies along the gastrointestinal tract. Esophageal squamous cell carcinoma (ESCC) is the most common cell type occurring at the upper and middle part of the esophagus. Surgery remains the mainstay treatment for this malignancy, however the long-term prognosis is modest with a 5-year overall survival of approximately 30%. To improve the treatment outcome of this cancer, multimodal treatment strategies including neoadjuvant chemoradiation have been implemented. Such pre-surgery treatment indeed leads to better clinical outcome and increases the chance for cure. Unfortunately patients who do not respond may have to undergo prolonged, unnecessary and potentially toxic treatments with no benefits. Currently, there is no reliable method for chemoradiation response prediction. To address this clinical limitation, we have established a non-invasive assay to stratify chemoradiation responders from non-responders. This study is systematically divided into three phases. In the discovery phase (phase I), we found 23 human microRNAs (out of 742 human microRNAs) with more than 2.5-fold elevation in serum from chemoradiation responders when compared to non-responders. In the selection and small-scale validation phase (phase II), small-scale validation in an independent cohort showed that microRNA-16 and microRNA-193b were two most powerful candidates for indicating chemoradiation responders. In the large-scale validation phase (phase III), we have further validated and confirmed the feasibility of microRNA-16 and miroRNA-193b as discriminators for chemoradiation response in a large cohort of more than a hundred patients. Standard curves were also constructed for these two microRNAs for copy number quantitation. In all, we have newly established a highly sensitive and specific blood-based assay with specific cut-offs for discriminating ESCC patients who are responsive to chemoradiation. This assay works by quantitating the serum level of microRNA-16 and microRNA-193b in ESCC patients, such that patients would be advised to receive pre-surgery chemoradiation if they have elevated levels of circulatory microRNA-16 and microRNA-193b. The development of this assay will benefit patient care by formulating individualized treatment plans. Note: This abstract was not presented at the meeting.
DescriptionPoster presentation: abstract no. 3989
Persistent Identifierhttp://hdl.handle.net/10722/217621
ISSN

 

DC FieldValueLanguage
dc.contributor.authorLee, NP-
dc.contributor.authorLai, KK-
dc.contributor.authorChan, KT-
dc.contributor.authorTong, DKH-
dc.contributor.authorLaw, S-
dc.date.accessioned2015-09-18T06:07:22Z-
dc.date.available2015-09-18T06:07:22Z-
dc.date.issued2015-
dc.identifier.citationThe 106th Annual Meeting of the American Association for Cancer Research (AACR 2015), Philadelphia, PA., 18-22 April 2015. In AACR Meeting Abstracts, 2015, v. 75 n. 15 suppl., abstract no. 3989-
dc.identifier.issn1948-3279-
dc.identifier.urihttp://hdl.handle.net/10722/217621-
dc.descriptionPoster presentation: abstract no. 3989-
dc.description.abstractEsophageal cancer is one of the most deadly malignancies along the gastrointestinal tract. Esophageal squamous cell carcinoma (ESCC) is the most common cell type occurring at the upper and middle part of the esophagus. Surgery remains the mainstay treatment for this malignancy, however the long-term prognosis is modest with a 5-year overall survival of approximately 30%. To improve the treatment outcome of this cancer, multimodal treatment strategies including neoadjuvant chemoradiation have been implemented. Such pre-surgery treatment indeed leads to better clinical outcome and increases the chance for cure. Unfortunately patients who do not respond may have to undergo prolonged, unnecessary and potentially toxic treatments with no benefits. Currently, there is no reliable method for chemoradiation response prediction. To address this clinical limitation, we have established a non-invasive assay to stratify chemoradiation responders from non-responders. This study is systematically divided into three phases. In the discovery phase (phase I), we found 23 human microRNAs (out of 742 human microRNAs) with more than 2.5-fold elevation in serum from chemoradiation responders when compared to non-responders. In the selection and small-scale validation phase (phase II), small-scale validation in an independent cohort showed that microRNA-16 and microRNA-193b were two most powerful candidates for indicating chemoradiation responders. In the large-scale validation phase (phase III), we have further validated and confirmed the feasibility of microRNA-16 and miroRNA-193b as discriminators for chemoradiation response in a large cohort of more than a hundred patients. Standard curves were also constructed for these two microRNAs for copy number quantitation. In all, we have newly established a highly sensitive and specific blood-based assay with specific cut-offs for discriminating ESCC patients who are responsive to chemoradiation. This assay works by quantitating the serum level of microRNA-16 and microRNA-193b in ESCC patients, such that patients would be advised to receive pre-surgery chemoradiation if they have elevated levels of circulatory microRNA-16 and microRNA-193b. The development of this assay will benefit patient care by formulating individualized treatment plans. Note: This abstract was not presented at the meeting.-
dc.languageeng-
dc.publisherAmerican Association for Cancer Research. The Journal's web site is located at http://www.aacrmeetingabstracts.org/-
dc.relation.ispartofAACR Meeting Abstracts-
dc.subjectMedical sciences-
dc.subjectCommunicable diseases-
dc.titleMicroRNA-16 and microRNA-193b as serological predictors for chemoradiation response in esophageal squamous cell carcinoma patients-
dc.typeConference_Paper-
dc.identifier.emailLee, NP: nikkilee@hku.hk-
dc.identifier.emailChan, KT: ktchan66@hku.hk-
dc.identifier.emailTong, DKH: esodtong@hku.hk-
dc.identifier.emailLaw, S: slaw@hkucc.hku.hk-
dc.identifier.authorityLee, NP=rp00263-
dc.identifier.authorityLaw, S=rp00437-
dc.identifier.doi10.1158/1538-7445.AM2015-3989-
dc.identifier.hkuros250909-
dc.identifier.volume75-
dc.identifier.issue15 suppl.-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats